{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:19:09Z","timestamp":1784063949666,"version":"3.55.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-022-01253-4","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:02:38Z","timestamp":1654081358000},"page":"885-896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barr\u00e9 Syndrome"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-8343","authenticated-orcid":false,"given":"Yusuf A.","family":"Rajabally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-022-01253-4_bib1","unstructured":"Guillain G, Barr\u00e9 JA, Strohl A. [Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes. 1916]. Ann Med Interne (Paris). 1999;150(1):24\u201332."},{"issue":"2","key":"10.1007\/s13311-022-01253-4_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"9497","key":"10.1007\/s13311-022-01253-4_bib3","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1007\/s13311-022-01253-4_bib4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","article-title":"The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study","volume":"51","author":"Jacobs","year":"1998","journal-title":"Neurology"},{"issue":"21","key":"10.1007\/s13311-022-01253-4_bib5","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM199511233332102","article-title":"Campylobacter jejuni infection and Guillain-Barr\u00e9 syndrome","volume":"333","author":"Rees","year":"1995","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1007\/s13311-022-01253-4_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/WNL.0b013e3181cff735","article-title":"Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh","volume":"74","author":"Islam","year":"2010","journal-title":"Neurology"},{"issue":"Pt 10","key":"10.1007\/s13311-022-01253-4_bib7","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/123.10.2171","article-title":"Haemophilus influenzae infection and Guillain-Barr\u00e9 syndrome","volume":"123","author":"Mori","year":"2000","journal-title":"Brain : a journal of neurology"},{"issue":"7","key":"10.1007\/s13311-022-01253-4_bib8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/cid\/cir074","article-title":"Guillain-Barr\u00e9 syndrome following primary cytomegalovirus infection: a prospective cohort study","volume":"52","author":"Orlikowski","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1007\/s13311-022-01253-4_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1212\/WNL.0000000000000111","article-title":"Guillain-Barr\u00e9 syndrome associated with preceding hepatitis E virus infection","volume":"82","author":"van den Berg","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-022-01253-4_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/jnnp-2016-314310","article-title":"Zika virus infection and Guillain-Barr\u00e9 syndrome: a review focused on clinical and electrophysiological subtypes","volume":"88","author":"Uncini","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1007\/s13311-022-01253-4_bib11","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1007\/s13311-022-01253-4_bib12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/jnnp-2020-324837","article-title":"Guillain-Barr\u00e9 syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions","volume":"92","author":"Filosto","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1007\/s13311-022-01253-4_bib13","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ana.25987","article-title":"Incidence, clinical, risk factors and outcomes of Guillain-Barr\u00e9 in Covid-19","volume":"89","author":"Fragiel","year":"2021","journal-title":"Ann Neurol"},{"issue":"Pt 1","key":"10.1007\/s13311-022-01253-4_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain : a journal of neurology"},{"issue":"Suppl","key":"10.1007\/s13311-022-01253-4_bib15","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1007\/s13311-022-01253-4_bib16","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barr\u00e9 syndrome","volume":"141","author":"Doets","year":"2018","journal-title":"Brain : a journal of neurology"},{"issue":"9","key":"10.1007\/s13311-022-01253-4_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","article-title":"Guillain-Barr\u00e9 and Miller Fisher syndromes\u2014new diagnostic classification","volume":"10","author":"Wakerley","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"22","key":"10.1007\/s13311-022-01253-4_bib18","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1212\/WNL.0000000000000481","article-title":"Paraparetic Guillain-Barr\u00e9 syndrome","volume":"82","author":"van den Berg","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0165-5728(98)00016-2","article-title":"Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barr\u00e9 syndrome?","volume":"86","author":"Koga","year":"1998","journal-title":"J Neuroimmunol"},{"issue":"8","key":"10.1007\/s13311-022-01253-4_bib20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1212\/WNL.0000000000002256","article-title":"Acute bulbar palsy as a variant of Guillain-Barr\u00e9 syndrome","volume":"86","author":"Kim","year":"2016","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-022-01253-4_bib21","first-page":"549","article-title":"A variant of Guillain-Barr\u00e9 syndrome with prominent bilateral peripheral facial nerve palsy\u2014facial diplegia and paresthesias","volume":"44","author":"Atsumi","year":"2004","journal-title":"Rinsho Shinkeigaku"},{"issue":"2","key":"10.1007\/s13311-022-01253-4_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJM195607122550201","article-title":"An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia)","volume":"255","author":"Fisher","year":"1956","journal-title":"N Engl J Med"},{"issue":"5032","key":"10.1007\/s13311-022-01253-4_bib23","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1136\/bmj.1.5032.1384","article-title":"Brain-stem encephalitis; further observations on a grave syndrome with benign prognosis","volume":"1","author":"Bickerstaff","year":"1957","journal-title":"Br Med J"},{"key":"10.1007\/s13311-022-01253-4_bib24","doi-asserted-by":"crossref","unstructured":"Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barr\u00e9 syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group. Annals of neurology. 1998;44(5):780\u20138.","DOI":"10.1002\/ana.410440512"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/jnnp-2014-307815","article-title":"Electrophysiological diagnosis of Guillain-Barr\u00e9 syndrome subtype: could a single study suffice?","volume":"86","author":"Rajabally","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01253-4_bib26","doi-asserted-by":"crossref","unstructured":"Van den Bergh PYK, Pi\u00e9ret F, Woodard JL, Attarian S, Grapperon AM, Nicolas G, et al. Guillain-Barr\u00e9 syndrome subtype diagnosis: a prospective multicentric European study. Muscle & nerve. 2018.","DOI":"10.1002\/mus.26056"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/jns.12104","article-title":"Cytoalbuminologic dissociation in Asian patients with Guillain-Barr\u00e9 and Miller Fisher syndromes","volume":"20","author":"Wong","year":"2015","journal-title":"Journal of the peripheral nervous system : JPNS"},{"issue":"10045","key":"10.1007\/s13311-022-01253-4_bib28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib29","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.expneurol.2011.11.039","article-title":"Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies","volume":"233","author":"Susuki","year":"2012","journal-title":"Exp Neurol"},{"issue":"10","key":"10.1007\/s13311-022-01253-4_bib30","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/brain\/awq260","article-title":"Conduction block in acute motor axonal neuropathy","volume":"133","author":"Kokubun","year":"2010","journal-title":"Brain : a journal of neurology"},{"issue":"2","key":"10.1007\/s13311-022-01253-4_bib31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1212\/01.wnl.0000194305.04983.ed","article-title":"Acute motor conduction block neuropathy followed by axonal degeneration and poor recovery","volume":"66","author":"Rajabally","year":"2006","journal-title":"Neurology"},{"issue":"15","key":"10.1007\/s13311-022-01253-4_bib32","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1523\/JNEUROSCI.4401-06.2007","article-title":"Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers","volume":"27","author":"Susuki","year":"2007","journal-title":"J Neurosci"},{"issue":"11","key":"10.1007\/s13311-022-01253-4_bib33","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.4049\/jimmunol.1301536","article-title":"Sialylation of Campylobacter jejuni endotoxin promotes dendritic cell-mediated B cell responses through CD14-dependent production of IFN-\u03b2 and TNF-\u03b1","volume":"191","author":"Huizinga","year":"2013","journal-title":"J Immunol"},{"issue":"4","key":"10.1007\/s13311-022-01253-4_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/157015909790031166","article-title":"Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies","volume":"7","author":"Jacob","year":"2009","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"10.1007\/s13311-022-01253-4_bib35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1007\/s13311-022-01253-4_bib36","doi-asserted-by":"crossref","unstructured":"Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2016;10(10):Cd001446.","DOI":"10.1002\/14651858.CD001446.pub5"},{"issue":"9","key":"10.1007\/s13311-022-01253-4_bib37","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/01.WNL.0000092019.53628.88","article-title":"A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barr\u00e9 syndrome","volume":"61","author":"Pritchard","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-022-01253-4_bib38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.410410304","article-title":"The French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome","volume":"41","author":"Appropriate number of plasma exchanges in Guillain-Barr\u00e9 syndrome","year":"1997","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01253-4_bib39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2016-314862","article-title":"Treatment dilemmas in Guillain-Barr\u00e9 syndrome","volume":"88","author":"Verboon","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8382","key":"10.1007\/s13311-022-01253-4_bib40","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0140-6736(84)91341-2","article-title":"Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy","volume":"1","author":"Greenwood","year":"1984","journal-title":"Lancet"},{"issue":"8415","key":"10.1007\/s13311-022-01253-4_bib41","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(84)90819-5","article-title":"Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy","volume":"2","author":"Osterman","year":"1984","journal-title":"Lancet"},{"issue":"8","key":"10.1007\/s13311-022-01253-4_bib42","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"The Guillain-Barr\u00e9 syndrome Study Group","volume":"35","author":"Plasmapheresis and acute Guillain-Barr\u00e9 syndrome","year":"1985","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01253-4_bib43","doi-asserted-by":"crossref","unstructured":"Efficiency of plasma exchange in Guillain-Barr\u00e9 syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 syndrome. Annals of neurology. 1987;22(6):753\u201361.","DOI":"10.1002\/ana.410220612"},{"key":"10.1007\/s13311-022-01253-4_bib44","doi-asserted-by":"crossref","unstructured":"Plasma exchange in Guillain-Barr\u00e9 syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome. Annals of neurology. 1992;32(1):94\u20137.","DOI":"10.1002\/ana.410320115"},{"key":"10.1007\/s13311-022-01253-4_bib45","doi-asserted-by":"crossref","unstructured":"Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2017;2(2):Cd001798.","DOI":"10.1002\/14651858.CD001798.pub3"},{"key":"10.1007\/s13311-022-01253-4_bib46","doi-asserted-by":"crossref","unstructured":"van der Mech\u00e9 FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. Dutch Guillain-Barr\u00e9 Study Group. N Engl J Med. 1992;326(17):1123\u20139.","DOI":"10.1056\/NEJM199204233261705"},{"key":"10.1007\/s13311-022-01253-4_bib47","doi-asserted-by":"crossref","unstructured":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group. Lancet. 1997;349(9047):225\u201330.","DOI":"10.1016\/S0140-6736(96)09095-2"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barr\u00e9 syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-022-01253-4_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000050777","article-title":"A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barr\u00e9 syndrome","volume":"46","author":"Diener","year":"2001","journal-title":"Eur Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01253-4_bib50","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Crit Care"},{"issue":"3","key":"10.1007\/s13311-022-01253-4_bib51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00365549509019016","article-title":"Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome","volume":"27","author":"G\u00fcrses","year":"1995","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barr\u00e9 syndrome: a randomized trial","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics"},{"issue":"2","key":"10.1007\/s13311-022-01253-4_bib53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain-Barr\u00e9 syndrome and contraindications to plasma exchange: 3 days versus 6 days","volume":"71","author":"Raphael","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9404","key":"10.1007\/s13311-022-01253-4_bib54","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomised trial","volume":"363","author":"van Koningsveld","year":"2004","journal-title":"Lancet"},{"key":"10.1007\/s13311-022-01253-4_bib55","doi-asserted-by":"crossref","unstructured":"Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2014;2014(9):Cd002063.","DOI":"10.1002\/14651858.CD002063.pub6"},{"issue":"3","key":"10.1007\/s13311-022-01253-4_bib56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/1531-8249(200003)47:3<314::AID-ANA6>3.0.CO;2-C","article-title":"Clinical features and response to treatment in Guillain-Barr\u00e9 syndrome associated with antibodies to GM1b ganglioside","volume":"47","author":"Yuki","year":"2000","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01253-4_bib57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.410400209","article-title":"Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barr\u00e9 syndrome","volume":"40","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01253-4_bib58","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/jnnp.70.4.560","article-title":"Indicators of rapid clinical recovery in Guillain-Barr\u00e9 syndrome","volume":"70","author":"Kuwabara","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1007\/s13311-022-01253-4_bib59","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/jnnp.72.5.680","article-title":"Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases","volume":"72","author":"Mori","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"14","key":"10.1007\/s13311-022-01253-4_bib60","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1212\/01.wnl.0000258673.31824.61","article-title":"Intravenous immunoglobulin therapy for Miller Fisher syndrome","volume":"68","author":"Mori","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1007\/s13311-022-01253-4_bib61","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jnnp-2012-302824","article-title":"Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome","volume":"84","author":"Shahrizaila","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1007\/s13311-022-01253-4_bib62","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"10.1007\/s13311-022-01253-4_bib63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jnnp-2011-301882","article-title":"Outcome and its predictors in Guillain-Barre syndrome","volume":"83","author":"Rajabally","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1007\/s13311-022-01253-4_bib64","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome","volume":"6","author":"van Koningsveld","year":"2007","journal-title":"The Lancet Neurology"},{"issue":"11","key":"10.1007\/s13311-022-01253-4_bib65","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-022-01253-4_bib66","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ana.21976","article-title":"Prediction of respiratory insufficiency in Guillain-Barr\u00e9 syndrome","volume":"67","author":"Walgaard","year":"2010","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01253-4_bib67","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr\u00e9 syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01253-4_bib68","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/jns.12286","article-title":"Second IVIg course in Guillain-Barr\u00e9 syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial","volume":"23","author":"Walgaard","year":"2018","journal-title":"Journal of the peripheral nervous system : JPNS"},{"issue":"2","key":"10.1007\/s13311-022-01253-4_bib69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2019-321496","article-title":"Original research: second IVIg course in Guillain-Barr\u00e9 syndrome with poor prognosis: the non-randomised ISID study","volume":"91","author":"Verboon","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1007\/s13311-022-01253-4_bib70","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib71","first-page":"24","article-title":"Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: results of a randomized, multicenter clinical trial","volume":"112","author":"Cafiero","year":"1992","journal-title":"Surgery"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib72","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1212\/WNL.0000000000007719","article-title":"Current treatment practice of Guillain-Barr\u00e9 syndrome","volume":"93","author":"Verboon","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-022-01253-4_bib73","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1212\/WNL.0000000000008742","article-title":"Thromboembolic risk with IVIg: incidence and risk factors in patients with inflammatory neuropathy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01253-4_bib74","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2011.05.035","article-title":"Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study","volume":"308","author":"Rajabally","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-022-01253-4_bib75","doi-asserted-by":"crossref","unstructured":"Rajabally YA, Afzal S. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. Journal of neurology. 2019;266(2):461\u20137.","DOI":"10.1007\/s00415-018-9157-4"},{"issue":"2","key":"10.1007\/s13311-022-01253-4_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003501","article-title":"Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries","volume":"9","author":"El-Ekiaby","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"10.1007\/s13311-022-01253-4_bib77","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1111\/trf.14301","article-title":"A randomized multicenter study: safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1\u201318 years with immune thrombocytopenia","volume":"57","author":"Elalfy","year":"2017","journal-title":"Transfusion"},{"issue":"8","key":"10.1007\/s13311-022-01253-4_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022862","article-title":"Small volume plasma exchange for Guillain-Barr\u00e9 syndrome in resource-limited settings: a phase II safety and feasibility study","volume":"8","author":"Islam","year":"2018","journal-title":"BMJ Open"},{"issue":"Suppl 3","key":"10.1007\/s13311-022-01253-4_bib79","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10072-010-0382-6","article-title":"The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases","volume":"31","author":"Bruno","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-022-01253-4_bib80","doi-asserted-by":"crossref","unstructured":"Krajnc N, Bsteh G, Berger T, Mares J, Hartung HP. Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management. Neurotherapeutics. 2022:1\u201321.","DOI":"10.1007\/s13311-022-01224-9"},{"issue":"10","key":"10.1007\/s13311-022-01253-4_bib81","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s12264-020-00525-3","article-title":"Monoclonal antibody-based treatments for neuromyelitis optica spectrum disorders: from bench to bedside","volume":"36","author":"Zhu","year":"2020","journal-title":"Neurosci Bull"},{"issue":"5","key":"10.1007\/s13311-022-01253-4_bib82","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"issue":"Pt 5","key":"10.1007\/s13311-022-01253-4_bib83","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain : a journal of neurology"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib84","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","article-title":"Inhibition of complement in Guillain-Barr\u00e9 syndrome: the ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"Journal of the peripheral nervous system : JPNS"},{"issue":"4","key":"10.1007\/s13311-022-01253-4_bib85","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6610","article-title":"A prospective, multicenter, randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with Guillain-Barr\u00e9 syndrome (GBS): protocol of Japanese Eculizumab Trial for GBS (JET-GBS)","volume":"5","author":"Yamaguchi","year":"2016","journal-title":"JMIR Res Protoc"},{"issue":"6","key":"10.1007\/s13311-022-01253-4_bib86","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"The Lancet Neurology"},{"issue":"6","key":"10.1007\/s13311-022-01253-4_bib87","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/1091581817740873","article-title":"Nonclinical development of ANX005: a humanized Anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases","volume":"36","author":"Lansita","year":"2017","journal-title":"Int J Toxicol"},{"issue":"8","key":"10.1007\/s13311-022-01253-4_bib88","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/jnr.22330","article-title":"Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barr\u00e9 syndrome","volume":"88","author":"Usuki","year":"2010","journal-title":"J Neurosci Res"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib89","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/jnnp.54.1.51","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with anti-T cell monoclonal antibodies","volume":"54","author":"Feasby","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1007\/s13311-022-01253-4_bib90","first-page":"667","article-title":"Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1","volume":"70","author":"Archelos","year":"1994","journal-title":"Lab Invest"},{"key":"10.1007\/s13311-022-01253-4_bib91","doi-asserted-by":"crossref","unstructured":"Jung S, Toyka K, Hartung HP. T cell directed immunotherapy of inflammatory demyelination in the peripheral nervous system. Potent suppression of the effector phase of experimental autoimmune neuritis by anti-CD2 antibodies. Brain : a journal of neurology. 1996;119 ( Pt 4):1079\u201390.","DOI":"10.1093\/brain\/119.4.1079"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01253-4_bib92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0304-3940(97)00692-7","article-title":"Attenuation of experimental autoimmune neuritis in the Lewis rat by treatment with an antibody to L-selectin","volume":"235","author":"Archelos","year":"1997","journal-title":"Neurosci Lett"},{"issue":"7","key":"10.1007\/s13311-022-01253-4_bib93","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/jnen\/61.7.614","article-title":"Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen","volume":"61","author":"Yu","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01253-4_bib94","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/bmt.2008.81","article-title":"Rituximab-responsive Guillain-Barr\u00e9 syndrome following allogeneic hematopoietic SCT","volume":"42","author":"Ostronoff","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1007\/s13311-022-01253-4_bib95","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00415-009-5400-3","article-title":"Guillain-Barr\u00e9 syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?","volume":"257","author":"Jaso","year":"2010","journal-title":"J Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01253-4_bib96","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1529-8027.2007.00134.x","article-title":"Guillain-Barr\u00e9 syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma","volume":"12","author":"Terenghi","year":"2007","journal-title":"Journal of the peripheral nervous system : JPNS"},{"issue":"6","key":"10.1007\/s13311-022-01253-4_bib97","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-009-5437-3","article-title":"Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy","volume":"257","author":"Marsh","year":"2010","journal-title":"J Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01253-4_bib98","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000358292","article-title":"Successful treatment of refractory Guillain-Barr\u00e9 syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia","volume":"132","author":"Tzachanis","year":"2014","journal-title":"Acta Haematol"},{"issue":"7","key":"10.1007\/s13311-022-01253-4_bib99","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.leukres.2010.02.036","article-title":"Guillain-Barr\u00e9 syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature","volume":"34","author":"Abbi","year":"2010","journal-title":"Leuk Res"},{"key":"10.1007\/s13311-022-01253-4_bib100","doi-asserted-by":"crossref","unstructured":"van der Zwan M, Hesselink DA, Brusse E, van Doorn PA, van den Hoogen MWF, de Weerd AE, et al. Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients. Neurology(R) neuroimmunology & neuroinflammation. 2020;7(4).","DOI":"10.1212\/NXI.0000000000000721"},{"issue":"12","key":"10.1007\/s13311-022-01253-4_bib101","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1111\/ajt.16754","article-title":"Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients","volume":"21","author":"Kjellman","year":"2021","journal-title":"Am J Transplant"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01253-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01253-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01253-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:57:28Z","timestamp":1761807448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1878747923011108"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01253-4","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barr\u00e9 Syndrome","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01253-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}